OBJECTIVE： To investigate the effects and safety of rosuvastatin on blood lipid and thyroid nodules in elderly patients with dyslipidemia. METHODS： 70 elderly patients with dyslipidemia were selected and randomly divided into control group （33 cases） and treatment group （37 cases）. Control group was treated with routine treatment as abstain from tobacco and drink， low fat diet， Aspirin enteric-coated tablets 100 mg at bed time； treatment group was additionally treated with Rosuvastatin calcium tablet 10 mg at bed time， on the basis of control group. Both groups received the treatment for consecutive 12 weeks. BMI， blood lipid and the size of thyroid nodules were compared between 2 groups before and after treatment， and the occurrence of ADR was also observed. RESULTS： There was no significant difference in BMI between 2 groups before and after treatment （P＞0.05）. There was no significant difference in blood lipid level and the size of thyroid nodules between 2 groups before and after treatment （P＞0.05）. The blood lipid level and the size of thyroid nodule of 2 groups were improved significantly after treatment， and the treatment group was significantly better than the control group， with statistical significance （P＜0.05）. 2 pationts of creatment suffered from the increase of ALT but recovered withont angtreatment. CONCLUSIONS： Rosuvastatin can significantly improve blood lipid and decrease thyroid nodules in elderly patients with dyslipidemia with good safety.